Table 6 Psychometric Testing of Final Questionnaire (Reliability, Construct Validity, Responsiveness)

 • Cronbach’s Alpha

≥0.8

0.99

0.98

0.99

0.94

0.98

0.98

 • Test-retest (ICC) Baseline vs. Week 1/Week 5 versus Week 6

≥0.7

0.76/0.92

0.71/0.90

0.82/0.94

0.73/0.91

0.75/0.91

0.76/0.92

 • Convergent Validity at Baseline/End of Active Treatment

>0.4

  o GFI

0.73/0.80

0.75/0.84

0.62/0.69

0.64/0.75

0.73/0.77

0.72/0.76

  o SF-36 VT

0.52/0.66

0.52/0.68

0.43/0.57

0.46/0.60

0.53/0.65

0.50/0.62

  o FIQ Total

0.71/0.80

0.69/0.81

0.59/0.69

0.67/0.76

0.68/0.77

0.70/0.76

  o SF-36 PF

0.42/0.40

0.42/0.39

0.31/0.34

0.43/0.38

0.41/0.39

0.44/0.40

  o SF-36 PCS

0.41/0.50

0.41/0.50

0.28/0.40

0.43/0.50

0.41/0.49

0.43/0.49

 • Divergent validity at Baseline/End of Active Treatment

< Convergent

  o Mood

0.36/0.52

0.29/0.47

0.36/0.53

0.32/0.41

0.34/0.53

0.34/0.52

  o Cognitive function

0.06/0.47

0.04/0.39

0.07/0.54

0.08/0.36

0.03/0.48

0.13/0.47

  o SF-36 other scales

0.27/0.66

0.26/0.66

0.26/0.56

0.27/0.65

0.26/0.59

0.26/0.63

  o Sexual Function

0.18/0.21

0.15/0.17

0.18/0.23

0.14/0.17

0.19/0.22

0.19/0.21

 • Known-groups Validity

p < 0.05

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

 • Change from Baseline to End of Active Treatment

p < 0.05

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

 • Effect Size

0.8 and above (Large)

0.91

0.95

0.69

0.94

0.88

0.85